Fundz

Watching Regeneron Pharmaceuticals, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Regeneron Pharmaceuticals, Inc.

Filed: Jul 30, 2026CIK: 0000872589Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Regeneron Pharmaceuticals announced its second quarter 2026 financial results on July 30, 2026, providing investors with an overview of the company's operational performance and pipeline developments during the quarter ended June 30, 2026.

Key Takeaways

Regeneron released Q2 2026 financial and operating results on July 30, 2026

Results covered the quarter ended June 30, 2026 with key performance metrics included

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 30, 2026
Item2.02
CategoryFinancial Results
CIK0000872589
Accession #0000872589
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings

Regeneron Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.